Top Performing Companies To Invest In 2015

Click chart for more stock market data

NEW YORK (CNNMoney) The markets were rattled by a sharp Monday sell-off, but investors were relatively calmer Tuesday.

The Dow Jones Industrial Average, the S&P 500 and the Nasdaq were down just slightly in early trading.

Tuesday marks the eighth day of the government's shutdown. While the Dow has dropped roughly 200 points in that time, the markets are actually performing better than many had expected. All three major indexes remain up more than 13% for the year.

Despite heated posturing, many experts think the Democrats and Republicans will be able to reach a last-minute agreement to raise the debt ceiling before October 17 and avoid a default.

Tuesday is also the start of third-quarter earnings season, with results due after the closing bell from aluminum producer Alco (AA, Fortune 500)and Yum! Brand, (YUM, Fortune 500)the parent of KFC, Pizza Hut and Taco Bell.

Top 5 Forestry Stocks To Watch For 2016: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By David Zeiler]

  3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

Top Performing Companies To Invest In 2015: Japan Petroleum Exploration Co Ltd (JPTXF)

Japan Petroleum Exploration Co., Ltd. is a company principally involved in the energy business. The Company operates in four geological segments. The Japan segment involves in the production, purchase and sale of crude oil and natural gas in Japan, the contracting of drilling and refurbishment works, mud logging works, research works, geophysical exploration works, the provision of pipeline maintenance services and security guard services, the purchase and sale of petroleum products, the transportation of petroleum and natural gas products, as well as real estate management business. The North America segment involves in the exploration and development of crude oil and natural gas in North America. The Middle East segment involves in the development of crude oil and natural gas. The Others segment involves in the exploration, development and production of crude oil and natural gas in Southeast Asia. As of March 31, 2013, the Company had 26 subsidiaries and 17 associated companies. Advisors' Opinion:

• [By WWW.MARKETWATCH.COM]

  LOS ANGELES (MarketWatch) -- Japanese stocks have ended with losses in every session this week, and sure enough, the Nikkei Average (JP:NIK) was down 0.6% in early Friday trade, though off an opening 0.8% defecit, while the Topix carried a 0.7% loss. Overnight losses for the U.S. and further strength in the yen (with the dollar falling to 楼101.28 from 楼101.56 a day earlier) helped drag the market lower, as did results from Fast Retailing Co. (JP:9983) (FRCOF) , the shares of which hold the heaviest weighting on Nikkei Average. Fast Retailing said that while its Uniqlo brand was doing great business, weakness for its J Brand luxury demin label helped send September-May profit down 4% and prompted another cut to Fast's full-year outlook. Consequently, its shares traded 0.7% lower, though rivals Takashimaya Co. (JP:8233) and J. Front Retailing Co. (JP:3086) (JFROF) also saw losses of 0.6% and 0.5%, respectively. Among other decliners, Sony Corp. (JP:6758) (SNE) lost 0.7%, Toshiba Corp. (JP:6502) (TOSYY) fell 2.1%, Kawasaki Heavy Industries Ltd. (JP:7012) (KWHIY) fell 1.5%, Toyota Motor Corp. (JP:7203) (TM) and Nissan Motor Co. (JP:7201)

Top Performing Companies To Invest In 2015: Great Lakes Dredge & Dock Corporation(GLDD)

Great Lakes Dredge & Dock Corporation engages in the business of marine construction, primarily dredging, and commercial and industrial demolition primarily in the east, west, and Gulf Coasts of the United States. The company?s Dredging segment is involved in capital dredging projects consisting of primarily port expansion projects, land reclamations, trench digging for pipelines, tunnels and cables, and other dredging related to the construction of breakwaters, jetties, and canals; beach nourishment projects, which involve moving sand from the ocean floor to shoreline locations; and maintenance dredging that includes the re-dredging of previously deepened waterways and harbors to remove silt, sand, and other accumulated sediments, as well as lake and river dredging, inland levee and construction dredging, environmental restoration, and habitat improvement. Its Demolition segment provides commercial and industrial demolition services. It is involved in exterior demolition that comprises dismantling and demolition of structures and foundations; and interior demolition, which includes removing specific structures within a building. This segment also engages in site development, removal of asbestos and other hazardous materials, and remediation of contaminated demolition materials. The company serves federal, state, and local governments; foreign governments; domestic and foreign private concerns, such as utilities and oil companies; general contractors; corporations that commission projects; nonprofit institutions, such as universities and hospitals; and local government and municipal agencies. It has a fleet of 33 dredges, including 8 deployed internationally; 19 material transportation barges; 2 drill boats; and various other specialized support vessels. The company was formerly known as Lydon & Drews Partnership and changed its name to Great Lakes Dredge & Dock Corporation in 1905. The company was founded in 1809 and is headquartered in Oak Brook, Illinois.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Great Lakes Dredge & Dock (Nasdaq: GLDD  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Great Lakes Dredge & Dock (Nasdaq: GLDD  ) .

• [By Seth Jayson]

  There's no foolproof way to know the future for Great Lakes Dredge & Dock (Nasdaq: GLDD  ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.

Top Performing Companies To Invest In 2015: Tennant Company(TNC)

Tennant Company engages in the design, manufacture, and marketing cleaning solutions worldwide. The company offers floor maintenance and outdoor cleaning equipment; chemical-free cleaning technologies; and specialty surface coatings and related products for protecting, repairing, and upgrading floors. Its products are used to clean and coat surfaces in factories, office buildings, parking lots and streets, airports, hospitals, schools, warehouses, shopping centers, and other retail environments. The company also provides parts, consumables, and service maintenance and repair; business solutions, such as pay-for-use offerings, and rental and leasing programs; and cleaning technologies that enhance the performance of its cleaning equipment. In addition, it offers Green Machine 500ze, an electric vacuum street sweeper to clean crowded urban areas. The company serves building service contract cleaners, end-user businesses, healthcare facilities, and schools, as well as local, state, and federal governments through its direct sales and service organization, and authorized distributors. Tennant Company was founded in 1870 and is based in Minneapolis, Minnesota.

Advisors' Opinion:

• [By Seth Jayson]

  Tennant (NYSE: TNC  ) reported earnings on April 22. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Tennant missed estimates on revenues and missed estimates on earnings per share.

• [By Marc Bastow]

  Floor maintenance and cleaning service company Tennant (TNC) raised its quarterly dividend 11% to 20 cents per share payable June 6 to shareholders of record May 30.
  TNC Dividend Yield: 1.29%

Top Performing Companies To Invest In 2015: General Growth Properties Inc. (GGP)

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc was founded in 1986 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Myra P. Saefong]

  After the close Monday, fourth-quarter results are due from the Hartford Financial Services Group Inc. (HIG) , which is projected to report earnings of 90 cents per share, Edwards LifeSciences Corp. (EW) , expected to post earnings per share of 82 cents and General Growth Properties Inc. (GGP) , expected to report a profit per share of 35 cents. For its first quarter, Hologic Inc. (HOLX) �is expected to post earnings per share of 31 cents.

• [By Johanna Bennett]

  General Growth Properties (GGP) gained 2.6% to close at $20.82 after S&P Dow Jones Indices said late Wednesday that it would add the real-estate investment trust to the S&P 500 index next week,

• [By Adam Levine-Weinberg]

  I think J.C. Penney's best bet for generating cash is selling off a few of its most desirable stores. This is not a palatable strategy, as it means losing some of the highest-potential stores, but it could produce cash without severely diluting the interests of J.C. Penney shareholders or adding interest expense that J.C. Penney cannot afford. For example, Sears Holdings,�another struggling department store giant, was able to sell 11 stores to General Growth Properties (NYSE: GGP  ) for $270 million last year. Bill Ackman's Pershing Square hedge fund happens to be a major shareholder in General Growth.� This could open up an opportunity for J.C. Penney to pursue a similar deal -- if any of its real estate would be sufficiently valuable to General Growth.

• [By Dan Caplinger]

  Admittedly, Sears has had some success raising cash with outright sales of its assets. Last year, for instance, Sears sold nearly a dozen lucrative properties, including its crown-jewel Ala Moana location in Hawaii, to General Growth Properties (NYSE: GGP  ) for $270 million. As Fool contributor Adam Levine-Weinberg noted earlier today, the fact that major J.C. Penney investor Bill Ackman also has a big position in General Growth Properties boosts the odds that a potential deal will go through.

Top Performing Companies To Invest In 2015: Westell Technologies Inc.(WSTL)

Westell Technologies, Inc., through its subsidiaries, engages in the design, distribution, marketing, and servicing a range of broadband, digital transmission, remote monitoring, power distribution, and demarcation products used by telephone companies and other telecommunications service providers. It operates in three segments: Customer Networking Systems (CNS) equipment, Outside Plant Systems (OSP) equipment, and ConferencePlus services. The CNS equipment segment provides networking and high-speed transmissions products, such as modems, routers, versatile gateway devices, and wireless broadband home routers that allow service providers to deliver broadband services over existing copper, fiber, coax, or wireless infrastructures. The OSP segment offers next generation outdoor cabinets; enclosures; power distribution; fiber, Ethernet, and coax edge connectors; remote monitoring equipment; and DS1 and DS3 transmission plugs. This segment also markets and sells power distribu tion and remote monitoring solutions. The ConferencePlus services segment provides audio, Web, and video conferencing services to businesses and individuals. This segment sells its services directly to Fortune 1000 companies, and indirectly through its private reseller programs. The company offers its products through field sales organizations and selected distributors in the United States, as well as in Canada and Europe. Westell Technologies, Inc. was founded in 1980 and is headquartered in Aurora, Illinois.

Advisors' Opinion:

• [By Rich Smith]

  On Friday, the diversified manufacturer named Brian S. Cooper�to replace interim CFO Braden Waverley on May 28. Waverly will remain acting CFO until Cooper joins the company next month. Cooper comes to Federal Signal by way of smaller telecommunications equipment maker Westell Technologies (NASDAQ: WSTL  ) , where he has served as CFO since 2009.

• [By Rich Smith]

  Late last month, the networking equipment maker had to scramble when its acting chief financial officer, Tom Minichiello, announced plans to retire on July 12 to become the new CFO at Westell Technologies (NASDAQ: WSTL  ) . On Friday, though, just as the deadline was happening, Tellabs announced that it has found a replacement.